Ustekinumab (UST) | Adalimumab (ADA) | p-value | |
---|---|---|---|
n/N (%) | n/N (%) | ||
Published SEAVUE Results | 96/191 (50.3) | 93/195 (47.7) | - |
Predicted SEAVUE Results, Primary Analysis | 67/149 (44.9) | 62/135 (45.9) | 0.9 |
Sensitivity Analysis: Trials with High Capture of Outcomes | 67/149 (44.9) | 60/135 (44.4) | 1 |
Sensitivity Analysis: Complete Cases | 66/148 (44.6) | 65/128 (50.3) | 0.39 |
Sensitivity Analysis: Information Leakage | 67/149 (44.9) | 67/135 (49.6) | 0.47 |
Negative Control, No Normalization | 67/149 (44.9) | 119/239 (49.8) | 0.4 |